片頭痛治療の世界市場レポート 2025年

片頭痛治療の市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR11.2％で53億2,000万米ドルに成長します。予測期間の成長は、認知度向上と教育、モノクローナル抗体の出現、小児片頭痛への注目の高まり、非薬理学的介入の拡大、片頭痛研究のための世界的イニシアティブに起因しています。予測期間における主な動向としては、治療アプローチの進歩、ウェアラブルデバイスとデジタル治療、遠隔医療と遠隔診察、患者中心のケアモデル、ジェネリック医薬品市場の成長、経口CGRP阻害薬などが挙げられます。

画面への長時間露出の増加が片頭痛治療市場の成長を牽引すると予測されます。スクリーンへの露出とは、スマートフォン、タブレット、コンピュータ、テレビなどの電子スクリーンに長時間にわたって接することを指します。スクリーン露出の長期化の要因としては、リモートワークの増加、オンライン教育、デジタルエンターテインメント、社会的交流におけるテクノロジーへの依存度の高まりなどが挙げられます。片頭痛の治療は、長時間のスクリーン使用によって誘発されたり悪化したりする症状に対処するもので、薬物療法、生活習慣の改善、人間工学に基づいた負担の軽減と発作の予防を目的としています。例えば、2024年5月、英国議会内の保健機関である下院委員会は、2021年に子どものスクリーン利用時間が52％急増し、子どもや若者の25％近くが行動中毒を示すスマートフォンの利用パターンを示していると報告しました。その結果、スクリーンへの長時間露出が片頭痛治療市場の成長を牽引しています。

臨床試験の増加は、片頭痛治療市場拡大の起爆剤となっています。これらの臨床試験は、片頭痛に対する新たな医療介入の安全性と有効性を評価することを目的としており、ヒトを対象としています。個別化された治療戦略や潜在的により効率的な治療法に関する洞察を提供します。2023年5月のXtalksによると、ClinicalTrials.govには452,604件の臨床試験が登録されており、64,838件が積極的に参加者を求めています。この臨床試験の急増は、急成長する片頭痛治療市場に積極的に貢献しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の片頭痛治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の片頭痛治療市場：成長率分析
• 世界の片頭痛治療市場の実績：規模と成長, 2019-2024
• 世界の片頭痛治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界の片頭痛治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の片頭痛治療市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 反復性
• 前兆を伴う片頭痛
• 慢性
• その他のタイプ
• 世界の片頭痛治療市場：治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性治療または急性期治療
• 予防的治療
• 非薬物療法とデバイス
• 世界の片頭痛治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 在宅ケア
• その他のエンドユーザー
• 世界の片頭痛治療市場：エピソードのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 頻繁な片頭痛
• まれに起こる片頭痛
• 世界の片頭痛治療市場：前兆を伴う片頭痛のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 視覚的前兆
• 感覚的前兆
• スピーチまたは言語オーラ
• 世界の片頭痛治療市場：慢性のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 前兆のない慢性片頭痛
• 慢性片頭痛（前兆を伴う）
• 世界の片頭痛治療市場：その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 片麻痺性片頭痛
• 網膜片頭痛
• 月経性片頭痛
• その他の特定のタイプ

第7章 地域別・国別分析

• 世界の片頭痛治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の片頭痛治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 片頭痛治療市場：競合情勢
• 片頭痛治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Allergan PLC
• Abbott Laboratories
• Allodynic Therapeutics LLC
• AOBiome LLC
• AstraZeneca PLC
• Bausch Health Companies Inc.
• Boehringer Ingelheim International GmbH
• Dr. Reddy's Laboratories Limited
• Impel Pharmaceuticals Inc.
• AbbVie Inc.
• Alder BioPharmaceuticals Inc.
• Astellas Pharma Inc.
• Biohaven Pharmaceutical Holding Company Ltd.
• Bristol-Myers Squibb Company

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 片頭痛治療市場2029：新たな機会を提供する国
• 片頭痛治療市場2029：新たな機会を提供するセグメント
• 片頭痛治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Migraines, a neurological condition, are characterized by severe headaches typically felt on one side of the brain. These pulsating headaches are the primary symptom of this condition. Migraine treatment aims to alleviate these intense and often debilitating headaches by targeting the brain's pain pathways. By effectively blocking these pathways, the treatment can halt future migraine attacks and alleviate associated symptoms.

Different types of migraine treatments cater to varying migraine presentations. Episodic migraine treatment addresses instances where individuals experience headaches for 0-14 days per month. This form of treatment encompasses various acute options tailored specifically for episodic migraines. Available treatments include acute/abortive methods, preventive/prophylactic approaches, as well as non-pharmacological therapies and devices. These treatments find applications across diverse settings, including hospitals, clinics, homecare, and other end-user environments.

The migraine treatment market research report is one of a series of new reports from The Business Research Company that provides migraine treatment market statistics, including migraine treatment industry global market size, regional shares, competitors with a migraine treatment market share, detailed migraine treatment market segments, market trends and opportunities, and any further data you may need to thrive in the migraine treatment industry. This migraine treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The migraine treatment market size has grown strongly in recent years. It will grow from $3.18 billion in 2024 to $3.48 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to increased prevalence of migraines, increased healthcare expenditure, improved formulations of existing drugs, expansion of clinical research, development of novel therapies.

The migraine treatment market size is expected to see rapid growth in the next few years. It will grow to $5.32 billion in 2029 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to growing awareness and education, emergence of monoclonal antibodies, increasing focus on pediatric migraines, expansion of non-pharmacological interventions, global initiatives for migraine research. Major trends in the forecast period include advancements in therapeutic approaches, wearable devices and digital therapeutics, telemedicine and remote consultations, patient-centric care models, generic drug market growth, oral CGRP inhibitors.

The increase in prolonged screen exposure is anticipated to drive the growth of the migraine treatment market. Screen exposure refers to the duration individuals spend engaging with electronic screens, including those on smartphones, tablets, computers, and televisions. Factors contributing to prolonged screen exposure include the rise in remote work, online education, digital entertainment, and a greater reliance on technology for social interactions. Migraine treatments address symptoms that are triggered or exacerbated by extended screen time, encompassing medications, lifestyle changes, and ergonomic practices aimed at reducing strain and preventing attacks. For example, in May 2024, the House of Commons Committee, a health agency within the UK Parliament, reported that children's screen time surged by 52% in 2021, with nearly 25% of children and young people displaying smartphone usage patterns indicative of behavioral addiction. As a result, prolonged screen exposure is driving the growth of the migraine treatment market.

The escalating number of clinical trials stands as a catalyst for the migraine treatment market's expansion. These trials, involving human participants, aim to evaluate the safety and effectiveness of new medical interventions for migraines. They offer insights into personalized treatment strategies and potentially more efficient therapies. As per Xtalks in May 2023, there were 452,604 registered clinical studies on ClinicalTrials.gov, with 64,838 actively seeking participants-a significant increase from 2021's 365,000 registered trials. This surge in clinical trials actively contributes to the burgeoning migraine treatment market.

Product innovations are a prominent trend gaining traction in the migraine treatment market. Leading companies in the sector are introducing novel solutions, such as liquid formulations, to maintain their competitive edge. For example, in January 2022, BioDelivery Sciences International (BDSI), a US-based pharmaceutical firm, launched Elyxyb (celecoxib oral solution), designed for the acute treatment of migraines in adults, regardless of whether they experience aura. This liquid formulation facilitates rapid absorption in the small intestine, resulting in quicker relief compared to conventional tablets. This innovation is particularly advantageous for migraine sufferers who experience nausea or vomiting, as it eliminates the waiting time for a pill to dissolve. As the first and only FDA-approved ready-to-use oral solution for migraines, Elyxyb offers a more tolerable and efficient treatment option for managing the sudden, intense pain associated with migraines.

Major players in the migraine treatment market prioritize product approvals, such as the zavzpret (zavegepant) migraine nasal spray, to bolster market revenues. Zavzpret, a calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray, targets the acute management of adult migraines. Notably, Pfizer Inc. received FDA approval for zavzpret (zavegepant) in March 2023. This nasal spray offers immediate relief for adult migraine attacks, aiming to provide pain relief with a single spray. The FDA's endorsement marks a significant milestone for migraine sufferers seeking alternatives to oral medications for prompt pain relief.

In May 2022, Pfizer Inc., a prominent biopharmaceutical company based in the US, successfully completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd. for an estimated $11.6 billion. This strategic acquisition positions Pfizer to further its commitment in providing effective treatments for individuals worldwide afflicted by migraines. Biohaven Pharmaceutical Holding Company Ltd., also based in the US, possesses a diverse product portfolio focused on addressing neuropsychiatric diseases and neurological disorders.

Major companies operating in the migraine treatment market are Pfizer Inc., Eli Lilly and Company, Amgen Inc., GlaxoSmithKline PLC, Novartis AG, Bayer AG, Allergan PLC, Abbott Laboratories, Allodynic Therapeutics LLC, AOBiome LLC, AstraZeneca PLC, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories Limited, Impel Pharmaceuticals Inc., AbbVie Inc., Alder BioPharmaceuticals Inc., Astellas Pharma Inc., Biohaven Pharmaceutical Holding Company Ltd., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Endo International PLC, Impax Laboratories Inc., Johnson & Johnson Inc., Lannett Company Inc., Lupin Limited, Merck & Co. Inc., Mylan N.V.

North America was the largest region in the migraine treatment market in 2024. The regions covered in the migraine treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the migraine treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The migraine treatment market includes revenues earned by entities by providing branded and generic migraine treatment services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Migraine Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on migraine treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for migraine treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The migraine treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Types: Episodic; Migraine With Aura; Chronic; Other Types
• 2) By Treatment: Acute Or Abortive Treatment; Preventive Or prophylactic Treatment; Non-Pharmacological Therapies And Devices
• 3) By End-User: Hospitals; Clinics; Homecare; Other End-users
• Subsegments:
• 1) By Episodic: Frequent Episodic Migraine; Infrequent Episodic Migraine
• 2) By Migraine With Aura: Visual Aura; Sensory Aura; Speech Or Language Aura
• 3) By Chronic: Chronic Migraine Without Aura; Chronic Migraine With Aura
• 4) By Other Types: Hemiplegic Migraine; Retinal Migraine; Menstrual Migraine; Other Specific Types
• Companies Mentioned: Pfizer Inc.; Eli Lilly and Company; Amgen Inc.; GlaxoSmithKline PLC; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Migraine Treatment Market Characteristics

3. Migraine Treatment Market Trends And Strategies

4. Migraine Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Migraine Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Migraine Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Migraine Treatment Market Growth Rate Analysis
• 5.4. Global Migraine Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Migraine Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Migraine Treatment Total Addressable Market (TAM)

6. Migraine Treatment Market Segmentation

• 6.1. Global Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Episodic
• Migraine With Aura
• Chronic
• Other Types
• 6.2. Global Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Or Abortive Treatment
• Preventive Or Prophylactic Treatment
• Non-Pharmacological Therapies And Devices
• 6.3. Global Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Homecare
• Other End-users
• 6.4. Global Migraine Treatment Market, Sub-Segmentation Of Episodic, By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Frequent Episodic Migraine
• Infrequent Episodic Migraine
• 6.5. Global Migraine Treatment Market, Sub-Segmentation Of Migraine With Aura, By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Visual Aura
• Sensory Aura
• Speech Or Language Aura
• 6.6. Global Migraine Treatment Market, Sub-Segmentation Of Chronic, By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Migraine Without Aura
• Chronic Migraine With Aura
• 6.7. Global Migraine Treatment Market, Sub-Segmentation Of Other Types, By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hemiplegic Migraine
• Retinal Migraine
• Menstrual Migraine
• Other Specific Types

7. Migraine Treatment Market Regional And Country Analysis

• 7.1. Global Migraine Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Migraine Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Migraine Treatment Market

• 8.1. Asia-Pacific Migraine Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Migraine Treatment Market

• 9.1. China Migraine Treatment Market Overview
• 9.2. China Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Migraine Treatment Market

• 10.1. India Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Migraine Treatment Market

• 11.1. Japan Migraine Treatment Market Overview
• 11.2. Japan Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Migraine Treatment Market

• 12.1. Australia Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Migraine Treatment Market

• 13.1. Indonesia Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Migraine Treatment Market

• 14.1. South Korea Migraine Treatment Market Overview
• 14.2. South Korea Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Migraine Treatment Market

• 15.1. Western Europe Migraine Treatment Market Overview
• 15.2. Western Europe Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Migraine Treatment Market

• 16.1. UK Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Migraine Treatment Market

• 17.1. Germany Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Migraine Treatment Market

• 18.1. France Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Migraine Treatment Market

• 19.1. Italy Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Migraine Treatment Market

• 20.1. Spain Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Migraine Treatment Market

• 21.1. Eastern Europe Migraine Treatment Market Overview
• 21.2. Eastern Europe Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Migraine Treatment Market

• 22.1. Russia Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Migraine Treatment Market

• 23.1. North America Migraine Treatment Market Overview
• 23.2. North America Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Migraine Treatment Market

• 24.1. USA Migraine Treatment Market Overview
• 24.2. USA Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Migraine Treatment Market

• 25.1. Canada Migraine Treatment Market Overview
• 25.2. Canada Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Migraine Treatment Market

• 26.1. South America Migraine Treatment Market Overview
• 26.2. South America Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Migraine Treatment Market

• 27.1. Brazil Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Migraine Treatment Market

• 28.1. Middle East Migraine Treatment Market Overview
• 28.2. Middle East Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Migraine Treatment Market

• 29.1. Africa Migraine Treatment Market Overview
• 29.2. Africa Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Migraine Treatment Market Competitive Landscape And Company Profiles

• 30.1. Migraine Treatment Market Competitive Landscape
• 30.2. Migraine Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Migraine Treatment Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Allergan PLC
• 31.3. Abbott Laboratories
• 31.4. Allodynic Therapeutics LLC
• 31.5. AOBiome LLC
• 31.6. AstraZeneca PLC
• 31.7. Bausch Health Companies Inc.
• 31.8. Boehringer Ingelheim International GmbH
• 31.9. Dr. Reddy's Laboratories Limited
• 31.10. Impel Pharmaceuticals Inc.
• 31.11. AbbVie Inc.
• 31.12. Alder BioPharmaceuticals Inc.
• 31.13. Astellas Pharma Inc.
• 31.14. Biohaven Pharmaceutical Holding Company Ltd.
• 31.15. Bristol-Myers Squibb Company

32. Global Migraine Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Migraine Treatment Market

34. Recent Developments In The Migraine Treatment Market

35. Migraine Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Migraine Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Migraine Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Migraine Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer